
Merck and Cyprumed enter oral peptide partnership worth over $493m
Merck & Co – known as MSD outside of the US and Canada – and Cyprumed have entered into a partnership aimed at developing oral formulations of Merck’s peptides, with the deal worth over $493m. The agreement gives Merck non-exclusive global rights to …